FIELD: medicine.
SUBSTANCE: invention relates to medicine. Disclosed is a method for diagnosing breast cancer with Her2/neu receptor expression on a tumor cell membrane. Method involves checking antibodies for antigen detection in known antigen-positive cases of breast cancer by flow cytometry and determining the working titre of the antibodies. When staining cells for flow-cytometric determination of HER2/neu, together with FITC (fluorescein-isothiocyanate) –reduced HER2/neu antibodies, double and triple fluorescent labels are used, and further calculating the percentage of HER2/neu positive cells in the CD45-CD326+ gate, indicating the level of antigen expression based on the determination of the average fluorescence intensity from the previous calibration, membrane epitope HER2 recognized by therapeutic monoclonal antibodies is evaluated and the amount of antigen-positive cells and expression levels of the membrane antigen is evaluated.
EFFECT: invention provides higher diagnostic accuracy of Her2/neu-positive breast cancer.
1 cl, 1 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE PROGNOSIS OF THE EFFECTIVENESS OF BREAST CANCER THERAPY | 2021 |
|
RU2757590C1 |
| METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
| METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
| BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| CONJUGATE OF LUMINESCENT SILICON DIOXIDE NANOPARTICLES WITH RECOMBINANT SINGLE-DOMAIN C7B LAMA NANO-MONOANTIBODIES, CAPABLE OF SPECIFICALLY INTERACTING WITH RECOMBINANT HER2/NEU PROTEIN - ANALOGUE OF EPIDERMAL GROWTH FACTOR NATURAL RECEPTOR EGFR/ERBB OF HUMAN CELLS | 2017 |
|
RU2679075C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN MELANOMA | 2021 |
|
RU2766739C1 |
| ANTIBODY SPECIFICALLY REACTING WITH HER2/neu ONCOPROTEIN | 2010 |
|
RU2425840C1 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
